U.S. market Open. Closes in 16 minutes

BSX | Boston Scientific Corporation Stock Overview

(Stock Exchange: NYSE)
Day's Range 82.86 - 84.01
52 Week Range 48.35 - 84.12
Beta 0.79
Implied Volatility 22.31%
IV Rank 35.87%
Day's Volume 3,494,502
Average Volume 5,557,646
Shares Outstanding 1,472,630,000
Market Cap 123,192,862,650
Sector Healthcare
Industry Medical - Devices
IPO Date 1992-05-19
Valuation
Profitability
Growth
Health
P/E Ratio 68.01
Forward P/E Ratio N/A
EPS 1.23
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 48,000
Country USA
Website BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX's peers: ALGN, SYK, ABT, MDT, DXCM, EW, ZBH, ZIMV, STE, SNN, INMD, MASS, NNOX, PHG, TNDM
*Chart delayed
Analyzing fundamentals for BSX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is exceptionally good and Health is passable. For more detailed analysis please see BSX Fundamentals page.

Watching at BSX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on BSX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙